The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Eosinophilic Count as a Biomarker for Prognosis of Melanoma Patients and Its Importance in The Response to Immunotherapy
Abstract
AIM: The prognostic role of eosinophils in cancer has been controversial. Some entities such as gastrointestinal cancers show a better survival, while others such as Hodgkin's lymphoma a worse survival in patients with eosinophilia. Patients who exhibited an increase in eosinophils upon therapy with ipilimumab or pembrolizumab were shown to survive longer. We wanted to investigate whether eosinophilia is a prognostic marker in metastatic melanoma. METHODS: In total, 173 patients with metastatic melanoma from our data base (median age 60 years; n = 86 with immunotherapy, n = 87 without immunotherapy) were analyzed for eosinophil counts and survival over the course of 12 years. Eosinophilic count was detected by peripheral blood smear. The ethical committee had approved this retrospective study. RESULTS: Melanoma patients with eosinophilia at any point in their course of disease show a trend toward longer survival independently of their therapy. There is a statistically significant difference for the patients who survive at least 12 months (p < 0.005). In patients with checkpoint inhibitor therapy, survival was significantly prolonged in every patient with eosinophilia (p < 0.05). Furthermore, 69% of the patients treated with immunotherapy experienced at least once an eosinophilia of 5% or greater compared with 46% in the immunotherapy naive-group; for an eosinophilia of 10% values were 30 and 9%, respectively. Interestingly, in patients with more than 20% eosinophils (n = 7) survival was prolonged with a median of 35 months (range 19-60 months) as compared with 16 months (range 1-117 months). CONCLUSION: Eosinophilia is a prognostic marker in patients with metastatic melanoma.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“ICI-related eosinophilia was described initially with ipilimumab 120 and later with PD-1/PD-L1 inhibitors; additionally, it was frequently associated with a favorable response to ICIs.121e123”
From Autoimmune diseases and immune-checkpoint inhibitors for cancer therapy: Review of the literature and personalized risk-based prevention strategy (2020) · cites this paper as [120]
Citations
Cites
Safety and Tumor Responses with Lambrolizumab (Anti–PD-1) in Melanoma
Hamid, O., Robert, C., DAUD, A. I., Hodi, F. S., Hwu, W., Kefford, R. F., Wolchok, J. D., Hersey, P., Joseph, R. W., Weber, J. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1305133 · Cited by 3,427
Brahmer, J. R., Drake, C. G., WOLLNER, I. S., Powderly, J. D., Picus, J., Sharfman, W. H., Stankevich, E., Pons, A., Salay, T. M., McMiller, T. L., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.7609 · Cited by 2,967
Phan, G. Q., Yang, J. C., Sherry, R. M., Hwu, P., Topalian, S. L., Schwartzentruber, D. J., Restifo, N. P., Haworth, L. R., Seipp, C. A., Freezer, L. J., et al. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1533209100 · Cited by 1,575
Attia, P., Phan, G. Q., Maker, A. V., Robinson, M. R., Quezado, M. M., Yang, J. C., Sherry, R. M., Topalian, S. L., Kammula, U. S., Royal, R. E., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.06.205 · Cited by 1,012
Baseline Biomarkers for Outcome of Melanoma Patients Treated with Pembrolizumab
Weide, B., Martens, A., Hassel, J. C., Berking, C., Postow, M. A., Bisschop, K., Simeone, E., Mangana, J., Schilling, B., Di Giacomo, A. M., et al. (2016) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-16-0127 · Cited by 589
Self-citationCarretero, R., Sektioglu, I. M., Garbi, N., Salgado, O. C., Beckhove, P., & Hämmerling, G. J. (2015) · Nature Immunology · doi:10.1038/ni.3159 · Cited by 501
Gebhardt, C., Sevko, A., Jiang, H., Lichtenberger, R., Reith, M., Tarnanidis, K., Holland-Letz, T., Umansky, L., Beckhove, P., Sucker, A., et al. (2015) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-15-0676 · Cited by 367
Delyon, J., Mateus, C., Lefeuvre, D., Lanoy, E., Zitvogel, L., Chaput, N., Roy, S., Eggermont, A. M. M., Routier, E., & Robert, C. (2013) · Annals of Oncology · doi:10.1093/annonc/mdt027 · Cited by 318
Ikutani, M., Yanagibashi, T., Ogasawara, M., Tsuneyama, K., Yamamoto, S., Hattori, Y., Kouro, T., Itakura, A., Nagai, Y., Τακακι, S., et al. (2011) · The Journal of Immunology · doi:10.4049/jimmunol.1101270 · Cited by 314
Mackensen, A., Meidenbauer, N., Vogl, S., Laumer, M., Berger, J., & Andreesen, R. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.07.1100 · Cited by 297
Davis, B. P., & Rothenberg, M. E. (2014) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-13-0196 · Cited by 262
Tumour-associated eosinophilia: a review.
Lowe, D. G., Jorizzo, J. R., & Hutt, M. (1981) · Journal of Clinical Pathology · doi:10.1136/jcp.34.12.1343 · Cited by 258
Simson, L., Ellyard, J. I., Dent, L. A., MATTHAEI, K. I., Rothenberg, M. E., Foster, P. S., Smyth, M. J., & Parish, C. R. (2007) · The Journal of Immunology · doi:10.4049/jimmunol.178.7.4222 · Cited by 217
Legrand, F., Driss, V., Delbeke, M., Loiseau, S., Hermann, E., Dombrowicz, D., & Capron, M. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000446 · Cited by 177
Cormier, S. A., Taranova, A. G., Bedient, C. E., Nguyen, T. D., Protheroe, C. A., Pero, R. S., Dimina, D., Ochkur, S. I., O'Neill, K. R., Colbert, D. C., et al. (2006) · Journal of Leukocyte Biology · doi:10.1189/jlb.0106027 · Cited by 176
Eosinophilic Granulocytes and Damage-associated Molecular Pattern Molecules (DAMPs)
Lotfi, R., Lee, J. J., & Lotze, M. T. (2006) · Journal of Immunotherapy · doi:10.1097/01.cji.0000211324.53396.f6 · Cited by 172
Eosinophils in Cancer: Favourable or Unfavourable?
Sakkal, S., Miller, S., Apostolopoulos, V., & Nurgali, K. (2016) · Current Medicinal Chemistry · doi:10.2174/0929867323666160119094313 · Cited by 161
Samoszuk, M. K. (1997) · PubMed · Cited by 156
Involvement of eosinophils in the anti-tumor response
Gatault, S., Legrand, F., Delbeke, M., Loiseau, S., & Capron, M. (2012) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-012-1288-3 · Cited by 132
Prizment, A. E., Vierkant, R. A., Smyrk, T. C., Tillmans, L. S., Lee, J. J., Sriramarao, P., Nelson, H. H., Lynch, C. F., Thibodeau, S. N., Church, T. R., et al. (2016) · Modern Pathology · doi:10.1038/modpathol.2016.42 · Cited by 97
Lipson, E. J., Sharfman, W. H., Chen, S., McMiller, T. L., Pritchard, T. S., Salas, J. T., Sartorius-Mergenthaler, S., Freed, I., Ravi, S., Wang, H., et al. (2015) · Journal of Translational Medicine · doi:10.1186/s12967-015-0572-3 · Cited by 95
Faries, M. B., Hsueh, E. C., Ye, X., Hoban, M., & Morton, D. L. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-1540 · Cited by 91
Rivoltini, L., Colombo, M. P., Parmiani, G., Viggiano, V., Spinazzé, S., Santoro, A., & Takatsu, K. (1993) · International Journal of Cancer · doi:10.1002/ijc.2910540103 · Cited by 69
Schaefer, J. T., Patterson, J. W., Deacon, D. H., Smolkin, M. E., Petroni, G. R., Jackson, E. M., & Slingluff, C. L. (2010) · Journal of Translational Medicine · doi:10.1186/1479-5876-8-79 · Cited by 49
Ohashi, Y., Ishibashi, S., Suzuki, T., Shineha, R., Moriya, T., Satomi, S., & Sasano, H. (2000) · PubMed · Cited by 44
Murine hypodense eosinophils induce tumour cell apoptosis by a granzyme B-dependent mechanism
Costain, D. J., Guha, A. K., Liwski, R., & Lee, T. D. G. (2001) · Cancer Immunology Immunotherapy · doi:10.1007/pl00006690 · Cited by 35
The appearance of hypodense eosinophils during interleukin-2 treatment
Sedgwick, J. B., Frick, W. E., Sondel, P. M., Hank, J. A., Borden, E. C., & Busse, W. W. (1990) · Journal of Allergy and Clinical Immunology · doi:10.1016/0091-6749(90)90093-j · Cited by 32
Rodgers, S., Rees, R. C., & Hancock, B. W. (1994) · British Journal of Haematology · doi:10.1111/j.1365-2141.1994.tb04824.x · Cited by 28
Predictive immune markers in advanced melanoma patients treated with ipilimumab
Umansky, V., Utikal, J. S., & Gebhardt, C. (2016) · OncoImmunology · doi:10.1080/2162402x.2016.1158901 · Cited by 25
Eosinophils enable the antitumour T cell response
Minton, K. (2015) · Nature reviews. Immunology · doi:10.1038/nri3861 · Cited by 16
Samoszuk, M. K., Deng, T., Hamamura, M. J., Su, M., Asbrock, N., & Nalcioğlu, O. (2004) · American Journal Of Pathology · doi:10.1016/s0002-9440(10)63310-x · Cited by 16
Capobianco, A., Manfredi, A. A., Monno, A., Rovere, P. Q., & Rugarli, C. (2008) · Journal of Immunotherapy · doi:10.1097/cji.0b013e318174a512 · Cited by 14
Cited by
Sorted by citations
A new dawn for eosinophils in the tumour microenvironment
Grisaru‐Tal, S., Itan, M., Klion, A. D., & Munitz, A. (2020) · Nature reviews. Cancer · doi:10.1038/s41568-020-0283-9 · Cited by 315
Eosinophils: The unsung heroes in cancer?
Varricchi, G., Galdiero, M. R., Loffredo, S., Lucarini, V., Marone, G., Mattei, F., Marone, G., & Schiavoni, G. (2017) · OncoImmunology · doi:10.1080/2162402x.2017.1393134 · Cited by 288
Diehl, A., Yarchoan, M. M., Hopkins, A., Jaffee, E. M., & Grossman, S. A. (2017) · Oncotarget · doi:10.18632/oncotarget.23217 · Cited by 249
Exploiting innate immunity for cancer immunotherapy
Yi, M., Li, T., Niu, M., Mei, Q., Zhao, B., Chu, Q., Dai, Z., & Wu, K. (2023) · Molecular Cancer · doi:10.1186/s12943-023-01885-w · Cited by 250
Haanen, J., Ernstoff, M. S., Wang, Y., Menzies, A. M., Puzanov, I., Grivas, P., Larkin, J., Peters, S., Thompson, J. A., & Obeid, M. (2020) · Annals of Oncology · doi:10.1016/j.annonc.2020.03.285 · Cited by 222
Metadata
- Authors
- Moreira, A., Leisgang, W., Schuler, G., & Heinzerling, L.
- Affiliations
- Friedrich-Alexander-Universität Erlangen-Nürnberg (DE)
- Venue
- Immunotherapy
- Publisher
- Informa UK Limited
- Published
- 2017-01-27
- Volume
- 9
- Issue
- 2
- Pages
- 115-121
- ISSN
- 1750-743X (ISSN-L)
- 1750-7448
- OpenAlex
- W2581911737
- Cited by
- 147
- References
- 32
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 9 · 2023: 18 · 2022: 28 · 2021: 22 · 2020: 24 · 2019: 9 · 2018: 7 · 2017: 6
- FWCI
- 5.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Immunotherapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Inflammatory Biomarkers in Disease Prognosis
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Health Sciences › Medicine › Oncology › Cutaneous Melanoma Detection and Management
- Keywords
- eosinophilia, eosinophil count, metastatic melanoma, prognostic factors, survival, immune checkpoint inhibitors, pembrolizumab, ipilimumab, blood eosinophils
- MeSH terms
- Adult, Aged, Aged, 80 and over, Animals, Cell Count, Eosinophils, Female, Humans, Immunotherapy, Male, Melanoma, Middle Aged, Neoplasm Metastasis, Prognosis, Biomarkers, Tumor, Survival Analysis, Young Adult
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
